News from BioTrends Research Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

20 Jun, 2013, 09:00 ET Use of Erythropoiesis Stimulating Agents Has Declined Over the Past Year in the U.S. Dialysis Setting, While Oral Iron Use in Dialysis Has Increased

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use...


11 Jun, 2013, 10:00 ET Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in their...


05 Jun, 2013, 09:00 ET Phosphate Binder Use Has Declined Over the Past Two Years in the U.S. Dialysis Setting, While Sensipar Use in Hemodialysis has Declined Since Last Year

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use...


30 May, 2013, 10:24 ET For Multiple Sclerosis Treatment, Prescriber Base for Genzyme's Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of...


29 May, 2013, 09:00 ET Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost

BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that rheumatoid...


29 May, 2013, 09:00 ET Despite Lucentis's Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...


23 May, 2013, 10:00 ET The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided,...


06 May, 2013, 09:33 ET Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six...


02 May, 2013, 09:00 ET The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...


25 Apr, 2013, 09:00 ET Long-Term Safety, Reduction in Disease Activity/Flares and Sustained Efficacy are Among the Key Unmet Needs for New Systemic Lupus Erythematosus (SLE) Treatments

 BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the top...


24 Apr, 2013, 09:00 ET At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizer's Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds...


15 Apr, 2013, 12:00 ET The Significant Number Of Countries With Biosimilar Regulatory Pathways And A Global Desire For More Affordable Healthcare Support The Introduction Of A Global Regulatory Process For Biosimilars

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the...


15 Apr, 2013, 09:00 ET Hemodialysis Patient Share for Sanofi's Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that in...


08 Apr, 2013, 10:00 ET Both Biosimilar and Reference Biologics Companies Must consider Various Product-Specific and Regional Strategies to Navigate a Dynamic and Uncertain Global Market

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, with sales...


08 Apr, 2013, 09:00 ET Lack of Familiarity and Hospital Formulary Inclusion Pose Key Barriers to Dificlir Uptake in European Markets for the Treatment of CDAD

 BioTrends Research Group and Arlington Medical Resources in their TreatmentTrends®: Clostridium difficile Infections (EU) report find...


04 Apr, 2013, 10:00 ET ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May Be Impacted by the Fact That Nephrologists Report Initiating ESAs at Lower Hemoglobins

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, compared to...


02 Apr, 2013, 08:00 ET Incorporation of the Anti-JC Virus Antibody Assay and Oral DMAs, Including Aubagio, are Top of Mind Recent Changes in the Management of Multiple Sclerosis Patients for Surveyed U.S. Neurologists

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...


01 Apr, 2013, 08:15 ET Two New Strategic Reports Expand Coverage Of BioTrend's Biosimilars Advisory Service

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released two...


25 Mar, 2013, 11:00 ET Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drug's Limited Post-Marketing Experience and Risks of Infection and Malignancy

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, after...


25 Mar, 2013, 10:51 ET Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that,...